We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC Seeks to Kill 'Reverse Payments' Between Brands and Generics
FTC Seeks to Kill 'Reverse Payments' Between Brands and Generics
September 9, 2005
The practice of “reverse payments” between brand and generic drugmakers could become much more commonplace if the FTC is unsuccessful in its latest effort to abolish the patent settlement strategy.